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Introduction
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder caused by the expansion of a polyglutamine
tract in the N-terminal of huntingtin (htt), a 350-kD protein with
incompletely defined function [1]. Individuals with 40 or more
contiguous glutamine repeats will go on to develop HD within a
normal lifespan, whereas the disease shows incomplete pene-
trance in those with 36–39 repeats. At least eight other neurode-
generative diseases are caused by a polyglutamine expansion in
unrelated proteins, including several spinocerebellar ataxias, den-
tatorubral pallydoluysian atrophy and Kennedy’s disease.
The accumulation of aggregated mutant N-terminal htt frag-
ments in transgenic HD mice [2] and post-mortem HD neurons [3]
is consistent with the ability of mutant polyglutamine proteins to
aggregate in vitro [4]. Full-length htt is believed to undergo prote-
olytic cleavage leading to a highly toxic and aggregation prone 
N-terminal fragment in HD brains [5]. The aggregation of mutant
htt fragments has been proposed to mediate toxicity through var-
ious mechanisms including aberrant interactions and subsequent
coaggregation of essential cellular proteins such as CBP and TBP
[6, 7], disturbing protein folding homeostasis [8] and impairment
of the ubiquitin-proteasome system (UPS) [9].
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Abstract
Huntington’s disease (HD) is an inherited neurodegenerative disease caused by the expansion of a polyglutamine tract in the protein
huntingtin (htt). HD brains are characterized by the presence of ubiquitin-positive neuronal inclusion bodies, suggesting that distur-
bances in the distribution of cellular ubiquitin may contribute to disease pathology. The fact that several neurodegenerative diseases are
caused by mutations in ubiquitin-processing enzymes and that the polyubiquitin genes are required for resistance to cellular stress led
us to investigate the effect of perturbing the ubiquitin system in HD. We crossed R6/2 transgenic HD mice with heterozygous polyubiq-
uitin Ubc knockout mice (Ubc/) and assessed the effect on the R6/2 neurological phenotype. Although the R6/2 phenotype was
largely unaffected, surprisingly we observed some subtle improvements in various behavioural activities correlating with heterozygous
Ubc knockout. Interestingly, immunoblot analysis revealed that the levels of monoubiquitylated histone H2A (uH2A), a modification
associated with gene repression, were significantly increased in the brains of R6/2 mice. Furthermore, the reduction of Ubc expression
in R6/2; Ubc/ mice largely prevented this increase in uH2A levels. However, we were not able to show by the use of a limited number
of quantitative RT-PCR assays that changes in the amount of uH2A in the R6/2-Ubc mice had an effect on disease-associated transcrip-
tional abnormalities. These results suggest that the expression of aggregation-prone mutant htt causes disturbances to the ubiquitin
system, which may contribute to disease due to the diverse and important roles of ubiquitin.
Keywords: polyglutamine • Huntington’s disease • ubiquitin • aggregation • histone modification • neurodegeneration
J. Cell. Mol. Med. Vol 13, No 8B, 2009 pp. 2645-2657
#Present address: Department of Life Science, 
University of Seoul, 130–743, Korea.
*Correspondence to: Gillian P. BATES, 
Medical and Molecular Genetics, 
King’s College London School of Medicine, 
8th Floor Tower Wing, Guy’s Hospital, 
London SE1 9RT, UK.
Tel.: 44 2071883722
Fax: 44 2071882585
E-mail: gillian.bates@genetics.kcl.ac.uk
© 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
doi:10.1111/j.1582-4934.2008.00543.x
2646
Although investigations into UPS impairment as a prerequisite
for polyglutamine disease pathogenesis have revealed conflicting
results [9–13], it is now becoming clear that alterations in the
partitioning of ubiquitin into Lys-conjugated chains is tightly
associated with disease progression [14]. Because essential 
cellular processes such as transcription, DNA repair and endocy-
tosis are all regulated to a considerable extent by ubiquitin, per-
turbations in ubiquitin levels or its homeostasis could contribute
to cellular dysfunction in polyglutamine disease. In addition,
there is strong evidence that mutations in ubiquitin-processing
enzymes lead to neurodegenerative disease in humans. For
example, mutations in the E3 ubiquitin ligase Parkin lead to auto-
somal recessive juvenile Parkinson’s disease [15], whereas dis-
tinct point mutations in the deubiquitylating enzyme UCH-L1
gene have been associated with both increased and decreased
susceptibility to Parkinson’s disease [16, 17]. Furthermore,
knocking this gene out in mice leads to the neurodegenerative
condition gracile axonal dystrophy [18].
Ubiquitin is transcribed from four loci in mammals, and in
each case it is translated as a precursor protein. The 
Uba genes are translated as one ubiquitin monomer fused to
either the large ribosomal subunit L40 (Uba52) or the small
ribosomal protein S27a (Uba80) [19]. The remaining ubiquitin
genes Ubb and Ubc encode stress-inducible polyubiquitin 
precursor proteins of around 3–4 or 9–11 monomers, respec-
tively [20, 21], which are cleaved into monomeric ubiquitin 
by cellular deubiquitylating enzymes. Studies in yeast suggest
that the ribosome-fusion genes provide the bulk of cellular
ubiquitin under normal circumstances, whereas the single
polyubiquitin gene is required for resistance to various cellular
stresses [22, 23].
We set out to investigate the regulation of ubiquitin in a
mouse model of HD and test the hypothesis that the mammalian
polyubiquitin genes would be protective against the toxic effects
of pathogenic polyglutamines. To investigate this, Ubc heterozy-
gous knockout mice (Ubc/) were generated [20] and
crossed to R6/2 transgenic HD mice. Contrary to expectations,
the loss of one Ubc allele actually improved performance of cer-
tain R6/2 behavioural activity phenotypes (rearing and centre-
rearing) while having no significant effect on other outcome
measures. Levels of free monomeric and total ubiquitin were
normal in the R6/2 brain, but the loss of one Ubc allele was suf-
ficient to cause a small but significant decrease in total brain
ubiquitin levels. Interestingly, we found that the levels of
monoubiquitylated histone H2A (uH2A) were dramatically
increased in R6/2 brains, but not in R6/2 brains heterozygous
for the Ubc allele. This suggests that the modest decrease in
total brain ubiquitin levels was sufficient to significantly reduce
increased uH2A levels in R6/2; Ubc/ mice. However, we
were unable to detect alterations in the expression of various
transcriptionally dysregulated disease genes between R6/2 and
R6/2; Ubc/ brains. These findings show that although a
polyubiquitin stress response is not activated in R6/2 mice, the
mutant htt-induced alterations in ubiquitin partitioning may be
important in disease pathogenesis.
Materials and methods
Mouse husbandry and behavioural assessment
Mice were housed and all experimental procedures were performed in
accordance with Home Office regulations. Mice had an unlimited supply 
of water and number 3 rodent breeding chow (Special Diet Services,
Witham, UK) and were subject to a 12-hr light and a 12-hr dark cycle. Mice
were housed 5 per cage with environmental enrichment as described pre-
viously [24]. The R6/2 mouse colony was maintained by backcrossing
R6/2 males to (C57BL/6JxCBA) F1 females (B6CBAF1/OlaHsd, Harlan Olac,
Bichester, UK), and R6/2 mice were identified by PCR genotyping as
described previously [24]. Ubc heterozygous knockout mice were gener-
ated on mixed (129/sv(J)  c57BL/6J) background and genotyped by PCR
as described previously [20]. Rotarod analysis and grip strength assess-
ment were performed as previously described [11], and mice were
weighed weekly to the nearest 0.1 g. Exploratory activity of mice was 
performed as previously described [25].
Western blot analysis
Mice were sacrificed by cervical dislocation and brains were quickly dis-
sected and frozen in isopropanol chilled with dry ice. Half brains were
homogenized in 1 ml of sodium phosphate buffer (20 mM sodium phos-
phate, 1% sodium dodecyl sulphate [SDS] and complete protease
inhibitors [Boehringer Mannheim, Mannheim, Germany]) and sonicated
for 30 sec. on ice (amplitude 40, Vibracell sonicator). Protein concentra-
tion of the lysates was determined using the BCA assay kit (Perbio,
Cramlington, UK) and 20 g protein were boiled for 1 min. then loaded
onto 12.5% SDS gels, separated and blotted onto PVDF membrane. For
ubiquitin immunoblotting, membranes were boiled for 30 min. in dH2O.
Membranes were blocked in 5% non-fat fried milk (NFDM) for 1 hr at
room temperature and probed with primary antibody in NFDM for 2 hrs
at room temperature. Blots were then washed four times in PBS and then
incubated with secondary antibody diluted in NFDM. Blots were washed
again in PBS and proteins were detected by chemiluminescence (ECL kit,
GE Healthcare, Amersham, UK) according to the manufacturer’s instruc-
tions. Protein levels were quantified on a Bio-Rad GS-800 Calibrated
Densitometer using Quantity-One® Software, and four brains of each
genotype were used for quantification. Primary antibodies and dilutions
were as follows: ubiquitin (Dako, Ely, UK) (rabbit pAb, 1:1000) and 
-tubulin (Sigma-Aldridge, Dorset, UK) (mAb, 1:2000). Secondary 
antibody dilutions were: HRP-linked anti-rabbit (Dako) (1:3000) and anti-
mouse (Vector Laboratories, Peterborough, UK) (1:5000). Membranes
were stripped by incubation in stripping buffer (100 mM 3-mercap-
toethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7) for 20 min. at 50C with
occasional agitation.
Indirect competitive enzyme-linked 
immunosorbent assay
Brain hemispheres were homogenized in 1 ml hypotonic buffer (10 mM
sodium phosphate, 0.1% digitonin and complete protease inhibitors) and
incubated on ice for 20 min. Protein concentration was measured using the
BCA kit (Perbio, Cramlington, UK) and adjusted to 5 g/l. Brain ubiquitin
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concentrations in untreated and Usp2-cc-treated samples were calculated
using a previously published protocol described in [26].
Quantitative real-time RT-PCR analysis
Mice were sacrificed by cervical dislocation and brains rapidly removed.
Striatum, cortex and cerebellum were dissected and flash-frozen in liquid
nitrogen and stored at –80C until use. RNA was prepared from dissected
striatum, cortex and cerebellum from animals at 14 weeks of age using the
RNeasy lipid mini kit (Qiagen, Crawley, UK) according to manufacturer’s
instructions. Quality and quantity of RNA was assessed using the RNA
nanochip method on a BioAnalzer (Agilent Technologies, South
Queensferry, UK). Reverse transcription of total RNA (5 g from cerebel-
lum and cortex, 2 g from striatum) was performed with 14 U/l MMLV
RTase (Invitrogen, Paisley, UK) in 50 mM KCl, 10 mM Tris-HCl (pH 9.0),
0.1% Triton X-100, 6.5 mM MgCl2, 10 mM DTT, 1 mM dNTPs, 10 ng/l
random hexamers with 0.35 U/l RNasin (Promega, Southampton, UK) at
10 @ 23C, 40 @ 37C, 5 @ 94C, 15 @ 4C then stored at –20C. The
RT reaction was diluted 1:10 in nuclease-free water (Sigma, Dorset, UK).
Taqman real-time PCR reactions were performed in triplicate with 5 l of
cDNA template in a 25-l reaction containing Precision Mastermix
(PrimerDesign), 300 nM primers and 200 nM probe using the Opticon 2
real-time PCR machine (MJ Research, GMI Inc., Ramsey, MN, USA).
Crossing threshold data were obtained during the logarithmic phase of
amplification where efficiency was close to 100%. Primer and probe
sequences used were: Uba52 Fwd 5-GTCAGCTTGCCCAGAAGTAC-3,
Rev 5-ACTTCTTCTTGCGGCAGTTG-3 (Sybr green); Uba80: Fwd 5-
GGCAAAATTAGCCGACTTCGT-3, Rev 5-TCAAAGTGGCTTCCCATGAAAA-3
probe 6-FAM-TGTCCTTCTGATGAATGTGGTGCTGGA-TAMRA; Ubb: Fwd 
5-CACTGAGTGACGAGAGGCTTG-3, Rev 5-CCAGCGCGTCGAAACA-3,
probe 6-FAM-CCGGTTCGGCGGTCTTTCTGTGA-TAMRA Ubc: Fwd
5-ATGCAGCTACCGCCTGGTT-3, Rev 5-GCAGCTGTCCTTCACATTCCA-3,
probe 6-FAM-AGGCGACATCAATTTCCTGGCGTG-TAMRA. All other assays
used are described in [27]. Relative quantification analyses were per-
formed using the 2		Ct method [28], using the geometric mean of three
reference genes as a calibrator [29]. All reference genes are available as
premixed reactions from Primer Design (Southampton, UK). Striatal
expression was normalized to the geometric mean of Atp5b, Eif4a2 and
Actb (fl-actin); cerebellar expression was normalized to the geometric
mean of Atp5b, Eif4a2 and Rpl13a.
Statistics
General Linear Model ANOVA and post hoc analysis was performed on
Excel and Minitab for behavioural, ELISA and real-time assays. For
Western blot quantification, Student’s t-test was performed.
Results
Ubiquitin gene expression in R6/2-Ubc mice
In order to investigate the potential role of the polyubiquitin
stress response on the progression of an HD mouse model, Ubc
heterozygous knockout mice were crossed with R6/2 transgenic
HD mice. Although complete Ubc knockout mice die in mid-ges-
tation, heterozygotes survive into adulthood and are pheno-
typically normal [20]. R6/2 males of breeding age were mated
with Ubc/ females to generate progeny of four genotypes:
WT, R6/2, Ubc/ and R6/2; Ubc/ in an equal ratio. Before
assessing the affect of Ubc heterozygosity on the mutant polyg-
lutamine-induced R6/2 neurological phenotype, expression of
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Fig. 1 Expression of the ubiquitin genes in R6/2-Ubc mice. Expression
of the four ubiquitin genes was normal in 14 week (end-stage) R6/2
striatum and cerebellum. Knockout of one Ubc allele can be seen to
reduce the levels of Ubc expression in R6/2 and non-R6/2 striatum and
cerebellum. Although significant in cerebellum (P 
 0.002) and cortex
(data not shown), this reduction of Ubc is not significant in the striatum
(P 
 0.147). Error bars show standard error of the mean.
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the ubiquitin genes in striatum and cerebellum was carried out
on all four genotypes. It was found that expression of all four
ubiquitin genes was normal in these end-stage (14 week) R6/2
brain regions (Fig. 1), and expression of Uba52, Uba80 and Ubb
was normal in mice heterozygous for Ubc. Importantly, the
expression of Ubc was reduced in both Ubc/ and R6/2;
Ubc/ brains at 14 weeks (Fig. 1). However, although this was
significant in cerebellum (GLM ANOVA: F(1,33) 
 11.95, P 
 0.002)
and cortex (data not shown), it fell out of statistical significance
in striatum (GLM ANOVA: F(1,31) 
 2.22, P 
 0.147). Because
heterozygous knockout of Ubc appears to cause reduction in
Ubc mRNA transcript, it was possible to test the effect of reduc-
tion of Ubc expression on the neurological phenotype of R6/2.
Reduction in Ubc does not affect R6/2 rotarod,
grip strength or weight loss
To investigate the importance of the Ubc polyubiquitin gene in HD
pathogenesis, 8–10 females of the four genotypes (WT, n 
 8;
Ubc/, n 
 9; R6/2, n 
 9; and R6/2; Ubc/, n 
 10) were
generated. The CAG repeat size of the R6/2 mice was well
matched, where CAG repeat means were 206.9 (R6/2) and 205.6
(R6/2; Ubc/). These female mice were dispersed carefully
between cages to ensure a variety of different genotypes from dif-
ferent mothers were represented in each cage, and all mice were
born within 3 days of one another. Mice were then subject to a 
battery of behavioural tests to assess any alteration of the R6/2
phenotype caused by loss of one Ubc allele.
Firstly, mice were subject to rotarod analysis at 4, 8, 10 and 
12 weeks of age. It was found that R6/2 mice performed worse
than non-R6/2 mice at 8 weeks (GLM ANOVA: F(1,35) 
 6.73, 
P 
 0.014) and onwards (Fig. 2A). The reduction of one Ubc allele
did not have a statistically significant effect on the rotarod per-
formance of R6/2 mice at any time-point (e.g. at 12 weeks there is
no interaction between R6/2 and Ubc genotypes GLM ANOVA:
F(1,35) 
 0.22, P 
 0.22).
R6/2-Ubc mice were also subject to a weekly analysis of grip
strength from 4 until 12 weeks of age. It was found that R6/2
mice performed significantly worse than non-R6/2 mice from 
5 weeks of age onwards (e.g. at 12 weeks, GLM-ANOVA: 
F(1,35) 
 34.58; P  0.001) (Fig. 2B). Although the deletion of
one copy of Ubc did not significantly affect the R6/2 deficit in
grip strength at any time-point (e.g. at 12 weeks, no interaction
between R6/2 and Ubc genotypes GLM ANOVA: F(1,35) 
 1.55; 
P 
 0.222), the trend of the graph shows that R6/2; Ubc/
mice have a small but consistently stronger grip than R6/2 at all
time-points (Fig. 2B).
The weight of R6/2-Ubc mice was monitored from 4 weeks
until 12 weeks. It was found that R6/2 mice weigh significantly
less than non-R6/2 mice from 4 weeks onwards (e.g. at 4 weeks
GLM ANOVA: F(1,35) 
 4.36; P 
 0.045) (Fig. 2C). In agreement
with the rotarod and grip strength data, the genetic reduction of
Ubc has no statistically significant effect on the R6/2 weight phe-
notype (e.g. at 12 weeks, no interaction between R6/2 and Ubc
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Fig. 2 Behavioural characterization of R6/2-Ubc mice. (A) Rotarod perform-
ance of R6/2 mice is significantly worse than that of non-R6/2 mice from 
8 weeks of age onwards. Knocking out one copy of Ubc has no effect on the
rotarod performance of R6/2 mice. (B) Grip strength of R6/2 mice is worse
than non-R6/2 mice from 5 weeks onwards. Knocking out one Ubc allele has
no significant effect on R6/2 grip strength. (C) R6/2 mice weigh significantly
less than non-R6/2 mice, and genetic reduction of Ubc has no statistically
significant effect on this. Error bars represent the standard error of the mean.
J. Cell. Mol. Med. Vol 13, No 8B, 2009
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genotypes GLM ANOVA: F(1,35) 
 1.46; P 
 0.236), but again
R6/2; Ubc/ mice appear to consistently weigh slightly more
than R6/2 mice at all time-points (Fig. 2C).
Ubc heterozygosity improves rearing 
and centre-rearing activities of R6/2
In addition to rotarod performance, grip strength assessment and
weight monitoring, R6/2-Ubc mice were placed in activity cages
and their spontaneous motor activity was monitored over a 1-hr
period (‘exploratory’ activity) every week from 4 weeks until 
12 weeks of age. Mice of all genotypes were very active to begin
with, and this initial activity gradually declined over the course of
the 1-hr period (Fig. 3). This effect was more pronounced for
Activity and Mobility than for Rearing and Centre-rearing, and is
reflected by the large incidence of significant P-values throughout
Table 1 under ‘Time’. From week 7 onwards, R6/2 mice were
observed to have less initial activity than non-R6/2 mice, therefore
their activity changes less than non-R6/2 over the 1-hr period 
(Fig. 3). This is reflected by the significant P-values in Table 1
under ‘Time X R6/2’, but is less obvious for centre-rearing than the
other three parameters however. Ubc genotype has no effect on
the time-dependent decrease in activity (see Table 1 under ‘Time X
Ubc’) and loss of one Ubc allele does not affect the change 
in activity over 1 hr in R6/2 mice (see Table 1 under ‘Time X 
R6/2; Ubc/’).
R6/2 mice appear to be less active than non-R6/2 mice from 
4 weeks until 12 weeks (Fig. 3) and this is statistically signifi-
cant from 8 weeks onwards (see Table 2 under ‘R6/2’). In con-
trast, Ubc genotype has no effect on activity (see Table 2 under
‘Ubc’). Interestingly, R6/2; Ubc/ mice appeared to be gener-
ally more active than R6/2 mice however (Fig. 3), suggesting
that the loss of Ubc allele improves certain polyglutamine-
induced disease phenotypes, albeit modestly. Indeed, this
increase in activity was found to be significant for rearing and
centre-rearing from 4 weeks of age until 12 weeks (see Table 2
under ‘R6/2 X Ubc’).
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Fig. 3 Exploratory activity of R6/2-Ubc mice. Graphs of exploratory activity, depicting 5-min. moving averages, for R6/2-Ubc mice are shown for (A)
4 weeks (B) 8 weeks and (C) 12 weeks of age. All mice tend to be more active when first placed in the cage, and then this initial activity declines over
the course of the hour. R6/2 mice display less initial activity than non-R6/2 from 7 weeks onwards (Table 1). R6/2; Ubc/ mice were observed to
be generally more active than R6/2 mice, and this is statistically significant for rearing and centre-rearing at all time-points (Table 2).
J. Cell. Mol. Med. Vol 13, No 8B, 2009
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Knocking out one Ubc allele reduces ubiquitin
protein levels
The behavioural assessment of R6/2-Ubc mice demonstrates 
that knocking out one allele of Ubc actually causes a modest
improvement of certain mutant N-terminal htt-mediated behav-
ioural activities in R6/2 mice. This was unexpected, as expression
of polyubiquitin genes such as Ubc is known to be protective
against a wide range of cellular insults in eukaryotes [22].
© 2008 The Authors
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Table of P-values showing effect of time on activity of R6/2-Ubc mice
from 4 to 12 weeks of age.
Week Activity Rearing
Centre-
rearing
Mobility
Time 4 0.001 0.004 0.604 0.001
5 0.001 0.004 0.107 0.001
6 0.001 0.385 0.374 0.005
7 0.001 0.113 0.092 0.008
8 0.001 0.017 0.192 0.001
9 0.001 0.014 0.038 0.001
10 0.001 0.001 0.028 0.001
11 0.001 0.001 0.071 0.001
12 0.001 0.001 0.007 0.001
Time X R6/2 4 0.728 0.631 0.564 0.517
5 0.217 0.482 0.377 0.293
6 0.118 0.501 0.635 0.271
7 0.007 0.023 0.34 0.045
8 0.001 0.001 0.202 0.002
9 0.001 0.026 0.286 0.002
10 0.001 0.046 0.341 0.001
11 0.001 0.001 0.039 0.001
12 0.001 0.001 0.003 0.001
Time X Ubc 4 0.869 0.417 0.408 0.735
5 0.642 0.1 0.342 0.356
6 0.195 0.45 0.504 0.462
7 0.838 0.936 0.655 0.783
8 0.332 0.586 0.616 0.274
9 0.429 0.779 0.719 0.399
10 0.295 0.489 0.776 0.246
11 0.478 0.193 0.132 0.466
12 0.129 0.199 0.02 0.139
Time X R6/2;
Ubc/
4 0.715 0.711 0.463 0.668
5 0.437 0.315 0.332 0.351
6 0.433 0.321 0.252 0.468
7 0.509 0.434 0.192 0.534
8 0.737 0.468 0.538 0.668
9 0.454 0.5 0.537 0.491
10 0.617 0.482 0.485 0.253
11 0.69 0.815 0.221 0.577
12 0.121 0.083 0.046 0.108
Table 1 The effect of time on R6/2; Ubc mice activity Table 2 General exploratory activity of R6/2; Ubc mice
Table of P-values showing changes in general exploratory activity of
R6/2-Ubc mice from 4 to 12 weeks of age.
Week Activity Rearing
Centre-
rearing
Mobility
R6/2 4 0.135 0.249 0.693 0.1
5 0.169 0.131 0.026 0.165
6 0.375 0.671 0.56 0.376
7 0.349 0.8 0.63 0.323
8 0.112 0.001 0.034 0.011
9 0.002 0.003 0.012 0.001
10 0.001 0.025 0.001 0.001
11 0.001 0.001 0.001 0.001
12 0.001 0.001 0.001 0.001
Ubc 4 0.462 0.262 0.343 0.236
5 0.174 0.31 0.678 0.228
6 0.451 0.361 0.594 0.416
7 0.343 0.074 0.066 0.388
8 0.921 0.869 0.884 0.608
9 0.955 0.339 0.706 0.851
10 0.782 0.715 0.148 0.935
11 0.626 0.577 0.273 0.572
12 0.962 0.215 0.052 0.821
R6/2 X Ubc 4 0.102 0.033 0.142 0.071
5 0.055 0.099 0.012 0.073
6 0.192 0.022 0.021 0.179
7 0.292 0.03 0.003 0.353
8 0.091 0.017 0.068 0.114
9 0.797 0.033 0.016 0.677
10 0.44 0.89 0.005 0.683
11 0.524 0.043 0.006 0.659
12 0.463 0.029 0.016 0.502
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Therefore, genetically reducing its expression in R6/2 mice was
hypothesized to result in a worsening of the disease. In order to
investigate possible explanations for this improvement in R6/2
behaviour, total brain hemisphere ubiquitin content was measured
across the four genotypes. Quantification of total ubiquitin in tis-
sues is notoriously difficult by immunoblot analysis [30] and is
complicated by the fact that ubiquitin is partitioned between its
free monomeric state, its covalent attachment to cellular proteins
(e.g. monoubiquitylation of histone H2A) and by its polymerization
into Lys-linked polyubiquitin chains. We therefore quantified total
ubiquitin in brain samples by converting all ubiquitin isopeptide
linkages into monomeric form by treatment of tissues with the
ubiquitin-specific protease Usp2-cc, followed by quantification by
an indirect competitive enzyme-linked immunosorbent assay
(ELISA) [26]. This technique was employed to measure ubiquitin
levels in 13-week-old brains from the R6/2-Ubc cross.
Treatment of brain extract with Usp2-cc followed by Western
blot analysis confirms that all visible ubiquitin conjugates were
successfully converted into monomeric ubiquitin (Fig. 4A). Six 
13-week-old brains of all four genotypes were then homogenized
and adjusted to the same protein concentration, and total ubiquitin
levels were measured in each genotype by treating brain samples
with Usp2-cc prior to performing the ELISA. Untreated samples
were also included in parallel to give an indication of what propor-
tion of cellular ubiquitin in mice of different genotypes exists as
monomer, as the ELISA is performed using an antibody that pref-
erentially detects monomeric ubiquitin. Commercially available
purified ubiquitin protein was attained and two standard curves of
known ubiquitin concentration were run alongside the untreated
samples on each plate (Fig. 4B). This allowed accurate quantifica-
tion of total ubiquitin levels in each sample, and it was found that
ubiquitin concentrations in the brain were consistent with those
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Fig. 4 Quantification of ubiquitin levels in R6/2-Ubc mice by indirect
competitive ELISA. (A) Treatment of brain samples with the ubiquitin-
specific protease Usp2-cc successfully converts all visible ubiquitin 
linkages into monomeric ubiquitin. Blots were stripped and reprobed with
-tubulin to show equal loading of protein. (B) Standard curve using 
precise ubiquitin concentrations shows the indirect competitive ELISA is
linear in the range of 2–500 ng of ubiquitin. (C) Total ubiqutin levels in the
R6/2 brain are not significantly different from those in WT, whereas the
loss of one Ubc allele does cause a small but significant reduction in 
ubiquitin levels. Ubiquitin levels are not significantly different between
Ubc/ mice and R6/2; Ubc/ mice treatment with Usp2-cc increases
measurable ubiquitin as the antibody preferentially detects monomeric
ubiquitin. Error bars represent standard errors of the mean.
J. Cell. Mol. Med. Vol 13, No 8B, 2009
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for mammalian cells [26] (Fig. 4C). In all genotypes, total tissue
ubiquitin levels were only modestly greater than  estimates of
monomeric ubiquitin in untreated samples (Fig. 4C). The presence
of N-terminal mutant htt did not significantly affect levels of total
ubiquitin in the R6/2 brain (no effect of R6/2 genotype on total ubiq-
uitin levels, GLM ANOVA: F(1,39) 
 0.8, P 
 0.378), whereas
knocking out one Ubc allele did cause a statistically significant
reduction in ubiquitin, consistent with reduced Ubc expression
(Ubc genotype has a significant effect on ubiquitin 
levels, GLM ANOVA: F(1,68) 
 11.16, P 
 0.001) (Fig. 4C). Likewise,
the levels of total ubiquitin in R6/2; Ubc/ brains were reduced
(Fig. 4C). Therefore, the loss of one Ubc allele causes a reduction
in total brain ubiquitin levels in R6/2 and non-R6/2 mice.
Monoubiquitylation of histone H2A (uH2A) 
is altered in R6/2-Ubc brains
Although ubiquitin quantification showed that levels of total ubiqui-
tin were reduced by loss of one Ubc allele, it was important to
examine ubiquitin profiles by Western blot in the brains of R6/2-
Ubc mice. This would highlight any alterations in the partitioning or
distribution of ubiquitin caused by the expression of mutant 
N-terminal htt. To investigate any changes in the ubiquitin balance
in R6/2 mice therefore, ubiquitin profiles of WT and R6/2 brain
hemispheres were compared. In keeping with the ELISA results,
levels of monomeric ubiquitin in 13-week-old R6/2 brains were
similar to WT (Fig. 5A). Interestingly, there was a significant
increase (P  0.001) in a prominent 25-kD band in R6/2 mice (Fig.
5A), which corresponds to monoubiquitylated histone H2A (uH2A).
This is the most abundant ubiquitylated protein in the cell and it has
been estimated that 5–15% of H2A is ubiquitylated [31, 32]. In light
of the finding that uH2A levels are increased in R6/2 brains, it was
of interest to determine the abundance of uH2A in R6/2; Ubc/
brains. Therefore, Western blots were performed to compare ubiq-
uitin profiles between R6/2 mice with one or both copies of the Ubc
allele. Although there was no obvious change in high molecular
weight ubiquitin conjugates or monomeric ubiquitin between the
two genotypes, uH2A levels were found to be significantly less in
R6/2; Ubc/ mice (P 
 0.016) (Fig. 5B). Similarly, although
increased levels of uH2A was observed in 8-week-old R6/2 brains,
R6/2; Ubc/ mice appear to be largely protected against this
effect (Fig. 5C). This suggests that the reduction in ubiquitin levels
in R6/2; Ubc/ mice reduces the amount of uH2A which is
observed in R6/2 mice. The increase in uH2A levels was not pres-
ent in 4-week-old R6/2 mouse brains (data not shown).
Transcription of disease genes is unchanged 
in R6/2; Ubc/ striatum
Histone modifications such as ubiquitylation are believed to affect
transcription by altering the association of DNA with proteins that
regulate chromatin structure. There was a strong likelihood there-
fore that increased levels of uH2A in the R6/2 brain was relevant
to disease pathology, as transcriptional dysregulation is believed
to be a central pathogenic mechanism in HD [33]. The fact that
increased uH2A abundance in R6/2 brains is largely prevented in
R6/2; Ubc/ mice raised the possibility that uH2A-mediated
gene expression changes may be related to the observed improve-
ment of certain disease behaviours in these mice.
To investigate this further, quantitative real-time RT-PCR analy-
sis was carried out in 13-week-old R6/2-Ubc on several genes
expressed in striatum, which are known to be dysregulated in the
R6/2 brain [27]. The genes examined were: cannabinoid CB1 
receptor (Cnr1), dopamine D2 receptor (Drd2), dopamine and cAMP 
regulated phosphoprotein (Darpp32) and proenkephalin (Penk1).
These assays were performed on cDNAs from the four geno-
types of the R6/2-Ubc cross (where n 
 at least 6 per genotype).
As expected, expression of all four striatal genes was down-
 regulated in R6/2 brains relative to non-R6/2 (GLM ANOVA: Cnr1
F(1.31) 
 88.16, P  0.000; Drd2 F(1.31) 
 15.7, P 
 0.000;
Darpp32 P(1.31) 
 108.75, P  0.000; Penk1 F(1.31) 
 30.2, 
P  0.000) (Fig. 6). However, the loss of one Ubc allele did not
increase the expression of any of the four genes in R6/2 (no inter-
action between R6/2 and Ubc genotypes, GLM ANOVA: Cnr1
F(1.31) 
 1.22, P 
 0.278; Drd2 F(1.31) 
 2.45, P 
 0.129;
Darpp32 F(1.31) 
 6.15, P 
 0.019; Penk1 F(1.31) 
 0.24, 
P 
 0.627). Therefore, the loss of one Ubc allele and prevention
of increased uH2A levels in R6/2; Ubc/ brains did not affect
expression of these dysregulated genes.
Discussion
In this study, we have set out to investigate the involvement of
ubiquitin in the pathogenesis of HD. As well as being central to 
protein degradation through the UPS, ubiquitin also plays a role in
various cellular processes such as transcription, DNA repair and
receptor-mediated endocytosis. Therefore, disturbances in ubiqui-
tin regulation could affect pathogenic processes in HD through a
variety of mechanisms. Further highlighting the importance of
ubiquitin processing and function to a healthy nervous system is
the occurrence of neurological disease in humans and mice caused
by mutations in ubiquitin-processing enzymes [16–18, 34].
To investigate the role of ubiquitin in HD, we crossed the well-
characterized R6/2 model of HD [35] with Ubc heterozygous
knockout mice [20] and evaluated the progeny using various
behavioural and biochemical analyses. Ubiquitin gene expression
analysis showed that the four ubiquitin genes are expressed 
normally in R6/2 mice. Knocking out one copy of Ubc caused a
subsequent drop in Ubc expression levels in the mouse brain,
allowing us to test what effect limiting polyubiquitin gene expres-
sion has on the pathogenic polyglutamine phenotype. In yeast, the
ribosome-fusion genes provide the majority of cellular ubiquitin
under normal circumstances, and the polyubiquitin gene is
required for survival under certain cellular stresses [22].
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Fig. 5 Ubiquitin profiles reveal an increase in monoubiquitylated histone H2A (uH2A) levels in R6/2. (A) Western blot with anti-ubiquitin antibody con-
firms there is no difference in free ubiquitin or high molecular weight ubiquitin conjugates in the R6/2 brain. Interestingly, the intensity of the 25-kD
band corresponding to monoubiquitylated histone H2A (uH2A) is significantly increased in R6/2 mice as confirmed by densitometry. Western blotting
with a specific H2A antibody showed that non-ubiquitylated H2A levels were lower in R6/2 mice, in keeping with increased uH2A levels (data not shown).
The blot was reprobed with -tubulin to confirm equal loading. (B) The increase in uH2A levels in R6/2 brains is reduced in brains of R6/2; Ubc/
J. Cell. Mol. Med. Vol 13, No 8B, 2009
2655
Therefore, it is likely that under normal mammalian physiological
conditions, expression of the Ubb and Ubc genes is required for
healthy cellular activity by providing a boost in free ubiquitin 
levels in response to cellular stress. It was therefore unexpected
that knocking out one copy of Ubc in R6/2 mice actually caused 
an improvement of certain mutant htt-mediated behaviours,
whereby exploratory activity (rearing and centre-rearing) of R6/2;
Ubc/ mice was increased with respect to R6/2 mice from 
4 weeks until 12 weeks.
Our finding that histone H2A, the first identified ubiquitin sub-
strate [36], shows a dramatic increase in its monoubiquitylated
form in R6/2 brains suggests that the balance of ubiquitin parti-
tioning is disturbed by mutant N-terminal htt. Histone H2A is the
most abundant ubiquitylated protein detectable in the cell, where
some 5–15% of H2A is ubiquitylated [31, 32]. Monoubiquitylation
of H2A (uH2A) is generally accepted to be involved in gene repres-
sion, and indeed has been shown to be required for polycomb
gene silencing and X chromosome inactivation [37–39]. The find-
ing that uH2A levels are robustly increased in the R6/2 brain there-
fore suggests that there may be a relationship between the ubiq-
uitin system and transcriptional alterations in HD. This link could
stem from disturbances in the overall ubiquitin balance as a result
of the effort exerted by the protein quality control arm of the ubiq-
uitin system (i.e. the UPS) in dealing with the proteotoxic effects
of mutant htt. The link between proteotoxic burden and distur-
bances in the ubiquitin equilibrium has recently been shown to
occur in cells upon heat shock or proteasome inhibition, where
uH2A levels were depleted in favour of the formation of high
molecular weight ubiquitin conjugates [40]. In addition, the accu-
mulation of polyubiquitin chains in R6/2 mice and human HD
patient brains suggests that disturbances to the ubiquitin system
may be a global consequence of mutant htt expression [14].
Remarkably, the increase in uH2A observed in R6/2 brains was
largely prevented in R6/2; Ubc/ mice. Interestingly, Kim et al.
[41] also recently found increased uH2A levels in R6/2 brains and
attributed this to a higher association of Bmi-1 (a component of
the hPRC1L E3 ubiquitin ligase for uH2A) with histones due to its
reduced binding to mutant htt. However, mutant N-terminal htt
protein levels, aggregation or transgene expression were not sig-
nificantly different between R6/2 and R6/2; Ubc/ mice (data
not shown), suggesting decreased Bmi-1 histone association is
not likely to explain the observed decrease in uH2A levels in R6/2;
Ubc/ mice. Although alterations in the levels or activity of spe-
cific uH2A deubiquitylases could affect uH2A levels in R6/2-Ubc
mice, the simplest explanation is that the modest reduction in
ubiquitin levels caused by Ubc heterozygosity limits the availabil-
ity of free ubiquitin to the hPRC1L uH2A E3 ligase complex.
It is unclear to what extent increased uH2A in HD mice con-
tributes to toxicity, or indeed how it may contribute to gene repres-
sion. Kim et al. recently showed that monoubiquitylation of H2A
appears to function upstream of di- and tri-methylation of histone
H3 at lys 9, both markers of heterochromatin [41]. In addition, H2A
monoubiquitylation has been shown to prevent di- and tri-methyla-
tion of histone H3 on lys 4, which is required for transcription initi-
ation (reviewed in [42]). Further cross-talk between uH2A and his-
tone modifications has been demonstrated whereby histone acety-
lation was shown to facilitate H2A deubiquitylation [42]. This is par-
ticularly intriguing in light of the fact that histones associated with
promoters of genes down-regulated in R6/2 mice are hypoacety-
lated, and that histone deacetylase inhibitors (HDACs) have been
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Fig. 6 Expression of dysregulated genes in 13-week R6/2-Ubc striatum.
The striatal expression of dysregulated R6/2 genes was compared
between the four genotypes. Although expression of all four genes was
reduced in R6/2 mice as expected, the loss of one Ubc allele did not have
any effect on R6/2 expression levels. Therefore, the reduction in uH2A
levels in R6/2; Ubc/ mice did not affect expression of these genes.
Interestingly, expression of Darpp32 was significantly increased in the
Ubc/ striatum (P 
 0.018). In addition, there was an interaction
between R6/2 and Ubc genotypes (P 
 0.016), which likely reflects the
lack of increased Darpp32 expression in R62; Ubc/ compared to that
observed in Ubc/. Error bars show the standard error of the mean.
mice as shown by Western blot and densitometry. (C) Increased H2A monoubiquitylation is also observed in 8-week R6/2 mice but not in R6/2; Ubc/
mice. Blots were reprobed with -tubulin antibody. It should be noted that detection of high molecular weight ubiquitin conjugates in Fig. 5 differs to
that depicted in Fig. 4. The lysis buffer used for the Western blot in Fig. 5 is incompatible with Usp2-cc activity, and immunoprobing with the anti-ubiq-
uitin antibody does not work as effectively in the buffer used for Usp2-cc digestion (Fig. 4). Error bars represent standard errors of the mean.
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shown to both decrease uH2A levels [43] and in a separate study
improve polyglutamine-induced behavioural abnormalities [44]. It
was therefore surprising that we were unable to show that the pre-
vention of increased levels of uH2A in R6/2; Ubc/ brains were
linked to changes in the expression of dysregulated striatal genes.
This may be because altered levels of uH2A are not associated with
the majority of the specific gene promoters investigated, or that the
decrease in levels of uH2A in R6/2; Ubc/ mice was insufficient
to exert a transcriptional effect. In support of the latter case, Kim et
al. have shown that increased uH2A levels are associated with the
Drd2 promoter in R6/2 striatum [41], whereas the global reduction
in uH2A levels in R6/2; Ubc/ mice did not affect Drd2 expres-
sion (Fig. 6). Therefore, the alterations in uH2A levels between R6/2
and R6/2; Ubc/ are either insufficient to affect gene expression
levels in vivo, or the effects are beyond the range of detection in our
study. Alternatively, the lack of transcriptional changes in R6/2;
Ubc/ mice may suggest that the modest improvements in
behaviour and changes in uH2A levels are in large part due to under-
lying alterations in protein ubiquitylation and folding. Indeed, it
would be interesting to investigate which other cellular proteins
show mutant htt-induced differential mono- or polyubiquitylation
and how these may affect HD phenotypes. This may add insights
into, for example, the growing idea that UPS activity in HD neurons
may vary depending on subcellular localization [13].
Given that the expression of N-terminal mutant htt disturbs the
balance of protein folding homeostasis within organisms [8], it
would be expected that more misfolded proteins are tagged for
proteasomal destruction in R6/2 mice. This extra burden on the
UPS, while not necessarily compromising the overall efficiency of
the system, may in fact disturb the ubiquitin balance by tagging a
higher proportion of proteins with K48-linked polyubiquitin
chains. Indeed, the abundance of K48-linked polyubiquitin chains
is increased in the brains of R6/2 and HD patients [14]. It there-
fore seems likely that the expression of an aggregation-prone pro-
tein such as mutant htt causes the redistribution of ubiquitin
within the cell by disturbing the balance of the cell’s protein refold-
ing and degradation machinery. This would doubtless have myriad
downstream consequences for the cell, given the diverse nature of
the roles and substrates of ubiquitin. Our findings that histone
H2A shows an increase in its monoubiquitylated form is possibly
just one downstream effect of many as a consequence of a mutant
htt-induced disturbance to the ubiquitin balance, and suggests
protein misfolding may induce downstream cellular abnormalities
through disturbing the ubiquitin system.
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